熱門資訊> 正文
BioRestorative在潜在许可协议谈判中激增
2024-06-13 20:01
- BioRestorative Therapies (NASDAQ:BRTX) traded ~20% higher in the premarket Thursday after the New York-based biotech said it has engaged in talks with a commercial-stage company to license IP rights related to its ThermoStem platform.
- Without naming its potential partner, BioRestorative (BRTX) said that the company held “substantive” discussions with a commercial-stage regenerative medicine company for a possible deal,
- ThermoStem represents BioRestorative’s (BRTX) metabolic program, designed to develop cell therapy candidates based on brown adipose (fat)- derived stem cells (BADSCs). Studies have shown the potential of BADSCs in treating obesity and related metabolic disorders.
- “It has been captivating to watch the scale, scope, and speed with which potential license partners have begun to show interest in our proprietary off-the-shelf ThermoStem® platform,” said Lance Alstodt, BRTX’s CEO.
More on BioRestorative Therapies
- BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript
- BioRestorative Therapies receives Nasdaq notice of non-compliance
- BioRestorative gains as FDA clears amendment to study on cell therapy candidate
- Seeking Alpha’s Quant Rating on BioRestorative Therapies
- Historical earnings data for BioRestorative Therapies
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
